DMAA
Drugs Made In America Acquisition Corp.10.36
-0.00-0.02%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
347.24MP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
10-Q
8-K
10-Q
Q2 FY2025 results
Drugs Made In America Acquisition Corp. posted a solid Q2 net income of $2.3M, fueled by $2.4M in interest from its $235.2M trust account, while general and administrative costs ticked up to $132K from $331K in Q1. For the half-year, net income hit $3.5M on $4.0M interest, against $463K expenses— a stark turnaround from the $55K loss in its brief 2024 startup phase. Cash outside the trust sits at a lean $822, with a $252K working capital deficit, but the sponsor covers shortfalls via a $696K receivable. No debt weighs on the books. Yet the real pressure builds: nailing a pharma merger by April 2026, or it's liquidation time.
10-Q
Q1 FY2025 results
Drugs Made In America Acquisition Corp. posted a net income of $1.3M for Q1 FY2025 ended March 31, 2025, driven by $1.6M in interest from its Trust Account while general and administrative costs hit $331K. The blank check company raised $230M through its January IPO and February over-allotment, depositing $231.2M into the Trust at $10.12 per redeemable share. Cash outside the Trust sits at a slim $923, with a $852K receivable from the sponsor covering expenses. No operations yet; focus remains on a pharmaceutical merger within 15 months, extendable to 21. Yet the clock ticks. Geopolitical tensions could disrupt the deal hunt.
10-K
FY2024 results
Drugs Made In America Acquisition Corp., a blank check company, reported no operating revenues for FY2024 ended December 31, 2024, with a net loss of $279,845 driven by general and administrative costs, while holding minimal cash of $1,351 as it prepared for its initial public offering. The IPO closed on January 29, 2025, raising $200 million in gross proceeds from 20 million units at $10 each, followed by an over-allotment exercise adding $30 million on February 18, 2025, for total gross proceeds of $230 million; simultaneously, the sponsor purchased 430,000 private placement units for $4.3 million. This positioned $231.15 million in a trust account by Q1 2025, providing ample liquidity for pursuing a business combination in the U.S. pharmaceutical sector within 15 months, extendable to 21. No capex or dividends occurred. Yet the sponsor's ties to a bankrupt entity raise red flags. Failure to complete a deal risks full redemption.
AAM
AA Mission Acquisition Corp.
10.65+0.03
DAAQ
Digital Asset Acquisition Corp.
10.17-0.01
ETHM
Dynamix Corporation
10.40-0.05
HCMA
HCM III Acquisition Corp.
10.08-0.01
IMAQ
International Media Acquisition
9.72+0.00
MAYA
Maywood Acquisition Corp.
10.31+0.00
MBAV
M3-Brigade Acquisition V Corp.
10.80-0.01
SDHI
Siddhi Acquisition Corp
10.25+0.00
SIMA
SIM Acquisition Corp. I
10.57+0.01
TDAC
Translational Development Acqui
10.42+0.00